About Protypia
Protypia is a Healthcare company based in Brentwood (United States) founded in 2017, and was acquired by Inotiv in July 2022. Provider of mass spectrometry based analytical solutions for drug safety and therapeutic development. Its focus areas include Life Sciences, Genomics, Genomics Services and Full Service. Its competitors include Nautilus Biotechnology, Somalogic and ProteinSimple; 3 of its 3 listed competitors have raised funding.
Company details
Protypia was founded in 2017 and is based in Brentwood, United States. Analytical support utilizing mass spectrometry is delivered for drug safety and therapeutic development within the biotechnology sector. Services encompass the examination of on-target and off-target protein interactions in covalent drugs, assessment of immune checkpoint proteins influencing immunotherapy responses, and proteogenomics analysis applied to cancer studies. Operations focus on precise molecular insights for pharmaceutical applications.
- Headquarters Brentwood, United States
- Stage Acquired
- SectorsHealthcare
- Website protypia.com
- Acquired by Inotiv (Jul 2022)
Investors in Protypia
Protypia has secured backing from 1 investor. Prominent investors backing the company include Inotiv Co.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Clinical development and regulatory services are provided by Inotiv. | 1974 | inotivco.com | Lafayette, United States |
Investor details for Protypia
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Protypia
2 dated milestones of Protypia across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Protypia is founded.
- Exit Acquired by Inotiv.
Competitors of Protypia
Protypia has 3 listed competitors in our database, 3 of them funded. They include Nautilus Biotechnology, Somalogic and ProteinSimple.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| nautilus.bio | 2016 | Seattle, United States | $103.26M | 134 | A proteomics platform is developed for analyzing the human proteome. | |
| somalogic.com | 1999 | Boulder, United States | $663.99M | 319 | Protein-based assays are developed for life science research. | |
| proteinsimple.com | 2004 | San Jose, United States | $114.29M | 157 | Provider tools to help researchers with protein analysis |
Detailed competitors of Protypia
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Protypia (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Protypia
Complete news archive for Protypia
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Protypia
Protypia was founded in 2017.
Protypia is headquartered in Brentwood, United States.
Protypia was founded in 2017 and is based in Brentwood, United States. Analytical support utilizing mass spectrometry is delivered for drug safety and therapeutic development within the biotechnology sector. Services encompass the examination of on-target and off-target protein interactions in covalent drugs, assessment of immune checkpoint proteins influencing immunotherapy responses, and proteogenomics analysis applied to cancer studies. Operations focus on precise molecular insights for pharmaceutical applications.
Protypia's top competitors include Somalogic, Nautilus Biotechnology and ProteinSimple.
Protypia has 1 investor. Key investors include Inotiv Co.
Yes. Protypia was acquired by Inotiv in July 2022.